Allergy Therapeutics plc (AGY.L)

4.5000 -0.3500 (-7.22%) At close: 05:06PM BST

Allergy Therapeutics plc

Dominion Way
Worthing BN14 8SA
United Kingdom
44 1903 844 700
https://www.allergytherapeutics.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 612

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Manuel Llobet	CEO & Executive Director	411.98k	N/A	1965
Mr. Shaun Antony Furlong	CFO & Executive Director	N/A	N/A	1976
Ms. Beverly Lees	Group Operations Director	N/A	N/A	N/A
Dr. Murray Skinner	Chief Scientific Officer	N/A	N/A	N/A
Mr. Santiago Puig	Business Development Director	N/A	N/A	N/A
Ms. Sue Baker	Head of Human Resources	N/A	N/A	N/A
Simon Piggott	Head of Clinical Science	N/A	N/A	N/A
Alan Bullimore	Head of Communication & Market Development	N/A	N/A	N/A
Mr. Russell Picket	Group Financial Controller	N/A	N/A	N/A
Karley Charlotte Mouatt Cheesman	Company Secretary	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Acarovac Plus, Pollinex, Synbiotics, and VLP Peanut. The company develops allergy vaccines for pollen, house dust mites, and animal fur, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.

Corporate governance

Allergy Therapeutics plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.